First Quarter 2023 Results

May 2, 2023



Forward Looking Statement and Explanatory Note

Statements contained in this presentation regarding the growth and prospects of the business, the Company's projected 2023 financial results, long-term objectives and all other statements in this presentation other than recitation of historical facts are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, estimates, uncertainties and other factors that may cause actual results to be materially different. Such factors include, but are not limited to, the following: the impact of general economic conditions, including inflation (and related monetary policy by governments in response to inflation), on economic activity and our operations; changes in macroeconomic and market conditions and market volatility, including interest rates and the effect on the credit markets and access to capital; the impact of global economic and geopolitical conditions, including inflation, recession and the COVID-19 pandemic; our ability to carry out our strategic initiatives and manage associated costs; our ability to recover potential claims under our event cancellation insurance; the timing of conferences and meetings, in particular our Gartner Symposium/Xpo series that normally occurs during the fourth quarter; our ability to achieve and effectively manage growth, including our ability to integrate our acquisitions and consummate and integrate future acquisitions; our ability to pay our debt obligations; our ability to maintain and expand our products and services; our ability to expand or retain our customer base; our ability to grow or sustain revenue from individual customers; our ability to attract and retain a professional staff of research analysts and consultants as well as experienced sales personnel upon whom we are dependent, especially in light of increasing labor competition; our ability to achieve continued customer renewals and achieve new contract value, backlog and deferred revenue growth in light of competitive pressures; our ability to successfully compete with existing competitors and potential new competitors; our ability to enforce and protect our intellectual property rights; additional risks associated with international operations, including foreign currency fluctuations; the impact on our business resulting from changes in international conditions, including those resulting from the war in Ukraine and current and future sanctions imposed by governments or other authorities; the impact of restructuring and other charges on our businesses and operations; cybersecurity incidents; risks associated with the creditworthiness, budget cuts, and shutdown of governments and agencies; our ability to meet ESG commitments; the impact of changes in tax policy (including the recently enacted Inflation Reduction Act of 2022) and heightened scrutiny from various taxing authorities globally; changes to laws and regulations; and other risks and uncertainties described under "Risk Factors" in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, Non-GAAP financial measures such as Adj. EBITDA, Adj. EBITDA Margin, Adj. Net Income, Adj. EPS and Free Cash Flow, as included in this presentation, are supplemental measures that are not calculated in accordance with U.S. GAAP. Definitions of these measures and reconciliations to the most-directly comparable GAAP measures are included in the appendix.

Unless otherwise indicated, or the content otherwise requires, all percentages indicated in this presentation are year-over-year growth rates.

The Company's SEC filings can be found on Gartner's website at investor.gartner.com and on the SEC's website at www.sec.gov. Forward looking statements included herein speak only as of May 2, 2023 and the Company disclaims any obligation to revise or update such statements to reflect events or circumstances after this date or to reflect the occurrence of unanticipated events or circumstances, except as required by applicable law or regulation.

Some totals may not add due to rounding.



Content

Consolidated Financials

1Q 2023 Financial ResultsPage 4Consolidated Financial SummaryPage 5Normalized P&L (Non-GAAP)Page 6

Segment Results

ResearchPage 7 - 8ConferencesPage 9ConsultingPage 10

Capital Allocation and Guidance

Capital Structure and Allocation Page 11
Updated 2023 Guidance Page 12

Appendix

Research Sales AppendixPages 14DefinitionsPages 15 - 161Q 2023 GAAP Financial StatementsPages 17 - 20Non-GAAP ReconciliationsPages 21 - 25



1Q 2023 Growth and Financial Results

Contract Value 10.4%	e (CV) \$4.5B	Consolidated I 11.6% FX Neutral: 14.3% 69.1% Contribution M	\$1,409M	Research Rev 7.1% FX Neutral: 9.5% 73.9% Contribution I	\$1,217M	Free Cash Flow \$144M
Global Techno 8.9%	ology Sales (GTS) CV \$3.5B	Adj. EBITDA 15.3% FX Neutral: 19.1% 26.9% Adj. EBITDA M	\$379M Iargin	Conference R 524% FX Neutral: 544% 41.4% Contribution I	\$65M	Share Repurchases \$107M
Global Busines 16.3%	ss Sales (GBS) CV \$1.0B	Adj. EPS \$2.88		Consulting Re 9.5%	evenue \$127M	
% increases above are F excludes divestiture and	FX Neutral at 2023 rates, I Russia as applicable.	Growth: 23.6%		FX Neutral: 14.1% 40.0% Contribution I	Margin	

Medium Term Guidance (unchanged)


Research	Conferences	Consulting	Revenue	EBITDA	EPS	Free Cash Flow
12 - 16 %	5 - 10 %	3 - 8 %	≥ 10 %	≥ Revenue Growth	≥ EBITDA Growth	≥ EBITDA Growth




Consolidated Financial Summary

Contract Value \$ billions @ '23 rates

Free Cash Flow \$ millions





\$ and shares in millions except per share amounts	1Q22	2Q22	3Q22	4Q22	1Q23	2022
Revenue	1,263	1,377	1,332	1,505	1,409	5,476
Y/Y Growth	14.4%	17.9%	15.2%	15.2%	11.6%	15.7%
Contribution	886	952	915	1,029	974	3,782
Contribution Margin	70.1%	69.2%	68.7%	68.4%	69.1%	69.1%
Adj. EBITDA	329	389	332	421	379	1,471
Y/Y Growth	2.6%	9.5%	8.5%	37.4%	15.3%	14.2%
Adj. EBITDA Margin	26.0%	28.3%	24.9%	28.0%	26.9%	26.9%
Adj. EPS	2.33	2.85	2.41	3.70	2.88	11.27
Y/Y Growth	16.5%	27.2%	18.7%	23.7%	23.6%	22.2%
Free Cash Flow	150	395	283	166	144	993
LTM Free Cash Flow	1,258	1,089	1,041	993	986	993
Y/Y Growth	34.9%	-7.2%	-18.4%	-20.7%	-21.6%	-20.7%
Avg. Diluted Shares	83.0	81.0	80.1	80.1	80.3	81.1

Note: All numbers are shown at 2023 FX rates where applicable, excludes divestiture and Russia as applicable.

Note: Consolidated contribution includes segment contribution and \$3 million of cost of services and product development – unallocated in 1Q23. The unallocated amounts consist of certain bonus and fringe costs recorded in consolidated Cost of services and product development that are not allocated to segment expense.

Free Cash Flow includes \$150 million, \$17 million and \$3 million of proceeds related to 2020 event cancellation insurance claims in 2Q21, 4Q21 and 1Q23, respectively.




Non-GAAP P&L

Revenues \$ millions



Adj. EBITDA \$ millions




\$ millions except per share amounts	1Q22	2Q22	3Q22	4Q22	1Q23	2022
Revenue	1,263	1,377	1,332	1,505	1,409	5,476
Less Cost of Services	<u>377</u>	<u>425</u>	<u>417</u>	<u>475</u>	<u>435</u>	<u>1,694</u>
Contribution	886	952	915	1,029	974	3,782
Less SG&A	618	605	613	645	657	2,481
Plus Equity Comp	32	24	21	13	45	91
Plus Other Adjustments *	<u>29</u>	<u>18</u>	<u>9</u>	<u>24</u>	<u>17</u>	<u>79</u>
Adj. EBITDA	329	389	332	421	379	1,471
Less Equity Comp	32	24	21	13	45	91
Less Depreciation	23	23	23	24	24	93
Less Non-GAAP Interest, net	30	29	29	29	26	117
Less Other Expense (Income)	<u>1</u>	<u>2</u>	<u>2</u>	<u>-1</u>	1	<u>5</u>
Adjusted Pre-tax Income	242	311	256	356	283	1,165
Less Adjusted Tax	<u>49</u>	<u>80</u>	<u>63</u>	<u>59</u>	<u>51</u>	<u>252</u>
Adjusted Net Income	193	231	193	297	231	914
Adj. EPS	2.33	2.85	2.41	3.70	2.88	11.27

^{*} Consists of direct and incremental expenses related to acquisitions and divestitures, impairment loss for lease related assets, facility-related exit costs and other non-recurring items.




Research Segment

Revenues \$ millions



Contribution Margin




\$ millions	1Q22	2Q22	3Q22	4Q22	1Q23	2022
Revenue	1,136	1,142	1,148	1,178	1,217	4,605
Y/Y Growth	16.0%	13.9%	10.7%	9.0%	7.1%	12.3%
Contribution	849	844	848	873	900	3,415
Contribution Margin	74.7%	73.9%	73.9%	74.1%	73.9%	74.2%
Subscription Revenue	1,026	1,038	1,045	1,074	1,110	4,183
Y/Y Growth	14.7%	13.2%	10.7%	8.9%	8.2%	11.8%
Non-subscription Revenue	111	104	102	105	107	422
Y/Y Growth	29.1%	20.8%	10.2%	9.4%	-2.9%	17.0%




Research Metrics

Contract Value \$ millions @ '23 rates



Quarterly Net Contract Value Increase (NCVI) \$ millions



See p.14 for GTS and GBS metrics

\$ millions	1Q22	2Q22	3Q22	4Q22	1Q23	2022
Contract Value	4,091	4,185	4,308	4,491	4,517	4,491
Contract Value FX Neutral Growth	16.5%	15.7%	14.7%	12.2%	10.4%	12.2%
Net Contract Value Increase (NCVI)	580	567	552	488	426	488
Quota Bearing Head Count	3,972	4,236	4,514	4,733	4,807	4,733
Y/Y Growth	3.6%	10.5%	16.6%	19.1%	21.0%	19.1%
Productivity (\$ thousands)	151	148	143	123	107	123
Quarterly Productivity (\$ thousands)	22	24	29	41	5	123
Client Enterprises	15,214	15,235	15,320	15,438	15,255	15,438
Contract Value / Enterprise (\$ thousands)	269	275	281	291	296	291


Note: All numbers are shown at 2023 FX rates where applicable, excludes divestiture and Russia as applicable. Historical Client Enterprises and associated metrics were updated to reflect the current structure.

NCVI and Productivity are on a rolling twelve month basis. Productivity is NCVI divided by opening period quota-bearing headcount. Quarterly Productivity are on a sequential basis. Quarterly Productivity is Quarterly NCVI divided by prior quarter quota-bearing head count. Quarterly NCVI for the full year is the sum of the four quarters. Quarterly Productivity for the full year is calculated as full year NCVI divided by opening period quota-bearing headcount.




Conferences Segment

Revenues \$ millions



Contribution Margin




\$ millions	1Q22	2Q22	3Q22	4Q22	1Q23	2022
Revenue	10	114	77	188	65	389
Y/Y Growth	-58.3%	95.1%	216%	76.0%	524%	81.5%
Contribution	-3	74	40	100	27	211
Contribution Margin	-27.8%	64.8%	52.3%	53.0%	41.4%	54.1%
Destination Conferences (#)	5	14	13	9	10	41
Destination Conference Attendees (#)	3,904	14,467	14,619	27,114	11,125	60,104


Note: All conferences in 1Q22 were virtual. All conferences in 1Q23 were in-person.

Consulting Segment

Revenues \$ millions



Contribution Margin



\$ millions	1Q22	2Q22	3Q22	4Q22	1Q23	2022
Revenue	116	121	107	138	127	482
Y/Y Growth	16.6%	13.9%	13.0%	17.1%	9.5%	15.2%
Contribution	51	50	37	51	51	190
Contribution Margin	44.0%	41.6%	34.8%	37.2%	40.0%	39.4%
Labor Revenue	96	95	90	96	97	378
Y/Y Growth	14.3%	10.7%	16.5%	10.9%	0.6%	13.0%
Contract Optimization Revenue	20	25	17	42	30	104
Y/Y Growth	29.1%	27.9%	-2.9%	35.9%	53.4%	24.7%
Backlog	141	147	156	134	161	134
Y/Y Growth	30.3%	45.7%	33.5%	23.8%	14.0%	23.8%
Billable Head Count	780	799	852	877	904	827
Y/Y Growth	4.9%	8.0%	13.7%	15.2%	15.9%	10.5%
Utilization Rate	72.0%	71.0%	66.1%	70.0%	66.6%	69.8%
Y/Y Change (bps)	433	49	433	-327	-541	147

Note: Backlog is at 2023 FX rates.



Capital Structure and Allocation


Capital Structure

- · Optimizes financial leverage benefits and financial flexibility
- Target 2-2.5x leverage¹
- ~\$200M cash is needed to run the business

Free Cash Flow deployment

- Expect to offset equity dilution
- Opportunistic, price sensitive stock repurchases
- Strategic value-enhancing tuck-in acquisitions
- · No current plans for material debt repayments

Share Repurchases \$ millions



^{~ \$950} million repurchase authorization remaining as of 3/31/2023

\$ billions	3/31/2023	Rate (2)	Maturity
Cash	0.9	nm	nm
Revolver	0.0	L + 125	2025
Term Loan	0.3	L + 125	2025
2028 Bonds	0.8	4.50%	2028
2029 Bonds	0.6	3.63%	2029
2030 Bonds	<u>0.8</u>	3.75%	2030
Total Debt	2.5	5.03%	
Revolver Unused Capacity	1.0	20 bps	
Interest Rate Swaps	0.4	3.04%	
% Debt With Fixed Rates	100%		
Leverage Ratios	1Q 2023	Bank Covenant	
Gross Debt/Adjusted EBITDA	1.6x	na	•
Net Debt/Adjusted EBITDA	1.0x	na	
Consolidated Leverage Ratio ³	1.4x	≤ 4.5x	
Debt Ratings	Corporate Rating	Unsecured Notes	
Moody's	Ba1	Ba1	'
S&P	BB+	BB+	



¹ Gross debt/Trailing twelve month Adjusted EBITDA

² Floating and total rates reflect LIBOR and spread as of date shown.

³ As defined in the Company's 2020 Credit Agreement.

2023 Guidance

\$ millions, except per share amounts; shares in millions

\$ at Reported Rates	Guidance as of February 7, 2023 At Least:	Guidance as of May 2, 2023 At Least:
Research Revenue	4,920	4,925
Conference Revenue	445	470
Consulting Revenue	500	505
Total Revenue	5,865	5,900
Adj. EBITDA	1,260	1,330
Adj. EPS	8.80	9.50
Free Cash Flow	920	920
Shares	~80	~80

- For Revenue, continue to allow for a higher than normal range of outcomes and tough compares, particularly with tech vendors
- All Conferences planned to run in-person
- Expenses reflect normal course growth hiring and the annualization of hiring done in 2022
- At current rates, FX will be a modest tailwind to growth for the full year, with the benefit in the second half

Depreciation & Amortization	Interest, net	Stock-Based Compensation	Effective Tax Rate	Capital Expenditures
~ 104	~ 115 GAAP &	~ 132	~ 23% GAAP &	~ 110
~ 91	~ 111 Non-GAAP		~ 22% Adi	





Appendix



Research: Additional Metrics

Global Technology Sales

\$ millions	1Q22	2Q22	3Q22	4Q22	1Q23	2022
Contract Value	3,246	3,305	3,391	3,524	3,534	3,524
Contract Value FX Neutral Growth	14.7 %	13.9 %	13.1 %	10.5 %	8.9 %	10.5 %
Net Contract Value Increase (NCVI)	416	404	393	334	288	334
Quarterly NCVI	56	59	86	133	10	334
Quota Bearing Head Count	3,009	3,237	3,473	3,630	3,666	3,630
Y/Y Growth	0.6 %	8.7 %	16.2 %	18.2 %	21.8 %	18.2 %
Productivity (\$ thousands)	139	135	132	109	96	109
Client Enterprises	13,578	13,586	13,642	13,726	13,541	13,726
Contract Value/ Enterprise (\$ thousands)	239	243	249	257	261	257
Wallet Retention	106.9 %	106.6 %	106.7 %	105.1 %	103.8 %	105.1 %
Client Retention	85.9 %	86.0 %	86.2 %	85.8 %	85.1 %	85.8 %
Global Business Sales						
\$ millions	1Q22	2Q22	3Q22	4Q22	1Q23	2022
Contract Value	845	880	917	967	983	967
Contract Value FX Neutral Growth	24.2 %	22.8 %	21.0 %	18.9 %	16.3 %	18.9 %
Net Contract Value Increase (NCVI)	165	163	159	154	138	154
Quarterly NCVI	32	35	37	50	16	154
Quota Bearing Head Count	963	999	1,041	1,103	1,141	1,103
Y/Y Growth	14.5 %	16.7 %	17.9 %	22.1 %	18.5 %	22.1 %
Productivity (\$ thousands)	196	191	180	170	143	170
Client Enterprises	4,661	4,721	4,780	4,843	4,849	4,843
Contract Value/ Enterprise (\$ thousands)	181	186	192	200	203	200
Wallet Retention	115.4 %	114.6 %	114.1 %	112.3 %	110.1 %	112.3 %
Client Retention	86.8 %	87.9 %	88.7 %	89.3 %	89.3 %	89.3 %

Note: All numbers are shown at 2023 FX rates where applicable, excludes divestiture and Russia as applicable. Historical Client Enterprises and associated metrics were updated to reflect the current structure. Enterprises that are clients of both GTS and GBS appear in both counts.

NCVI and Productivity are on a rolling twelve month basis. Productivity is NCVI divided by opening period quota-bearing headcount. Quarterly NCVI is on a sequential basis. Quarterly NCVI for the full year is the sum of the four quarters.



Definitions

Adjusted EBITDA and Adjusted EBITDA Margin: Represents GAAP net income (loss) adjusted for: (i) interest expense, net; (ii) tax provision (benefit); (iii) gain on event cancellation insurance claims, as applicable; (iv) gain/loss on divestitures, as applicable; (v) other (income) expense, net; (vi) stock-based compensation expense; (vii) depreciation, amortization, and accretion; (viii) loss on impairment of lease related assets, as applicable; and (ix) acquisition and integration charges and certain other non-recurring items. Adjusted EBITDA Margin represents Adjusted EBITDA divided by GAAP Revenue. We believe Adjusted EBITDA and Adjusted EBITDA Margin are important measures of our recurring operations as they exclude items not representative of our core operating results.

Adjusted Net Income: Represents GAAP net income (loss) adjusted for the impact of certain items directly related to acquisitions and other non-recurring items. These adjustments include: (i) the amortization of acquired intangibles; (ii) acquisition and integration charges and other non-recurring items; (iii) gain on event cancellation insurance claims, as applicable; (iv) gain/loss on divestitures, as applicable; (v) loss on impairment of lease related assets, as applicable; (vi) the non-cash (gain) loss on de-designated interest rate swaps, as applicable; and (vii) the related tax effect. We believe Adjusted Net Income is an important measure of our recurring operations as it excludes items that may not be indicative of our core operating results.

Adjusted EPS: Represents GAAP diluted EPS adjusted for the impact of certain items directly related to acquisitions and other non-recurring items. These adjustments include on a per share basis: (i) the amortization of acquired intangibles; (ii) acquisition and integration charges and other non-recurring items; (iii) gain on event cancellation insurance claims, as applicable; (iv) gain/loss on divestitures, as applicable; (v) loss on impairment of lease related assets, as applicable; (vi) the non-cash (gain) loss on de-designated interest rate swaps, as applicable; and (vii) the related tax effect. We believe Adjusted EPS is an important measure of our recurring operations as it excludes items that may not be indicative of our core operating results.

Free Cash Flow: Represents cash provided by operating activities determined in accordance with GAAP less payments for capital expenditures. We believe Free Cash Flow is an important measure of the recurring cash generated by the Company's core operations that may be available to be used to repay debt obligations, repurchase our stock, invest in future growth through new business development activities, or make acquisitions.

Foreign Currency Neutral (FX Neutral): We provide foreign currency neutral dollar amounts and percentages for our contract values, revenues, certain expenses, and other metrics. These foreign currency neutral dollar amounts and percentages eliminate the effects of exchange rate fluctuations and thus provide a more accurate and meaningful trend in the underlying data being measured. We calculate foreign currency neutral dollar amounts by converting the underlying amounts in local currency for different periods into U.S. dollars by applying the same foreign exchange rates to all periods presented.

Non-GAAP Interest: Interest expense, net excluding amortization of certain deferred financing fees.



Definitions of Key Metrics/Calculations

Segment Business Measurements

Research

Contract value represents the dollar value attributable to all of our subscription-related contracts. It is calculated as the annualized value of all contracts in effect at a specific point in time, without regard to the duration of the contract. Contract value primarily includes Research deliverables for which revenue is recognized on a ratable basis, as well as other deliverables (primarily Conferences tickets) for which revenue is recognized when the deliverable is utilized. Comparing contract value year-over-year not only measures the short-term growth of our business, but also signals the long-term health of our Research subscription business since it measures revenue that is highly likely to recur over a multi-year period. Our contract value consists of Global Technology Sales contract value, which includes sales to users and providers of technology, and Global Business Sales contract value, which includes sales to all other functional leaders.

Client retention rate represents a measure of client satisfaction and renewed business relationships at a specific point in time. Client retention is calculated on a percentage basis by dividing our current clients, who were also clients a year ago, by all clients from a year ago. Client retention is calculated at an enterprise level, which represents a single company or customer.

Wallet retention rate represents a measure of the amount of contract value we have retained with clients over a twelve-month period. Wallet retention is calculated on a percentage basis by dividing the contract value of our current clients, who were also clients a year ago, by the contract value from a year ago, excluding the impact of foreign currency exchange. When wallet retention exceeds client retention, it is an indication of retention of higher-spending clients, or increased spending by retained clients, or both. Wallet retention is calculated at an enterprise level, which represents a single company or customer.

Conference

Number of destination conferences represents the total number of hosted virtual or in-person conferences completed during the period. Single day, local meetings are excluded.

Number of destination attendees represents the total number of people who attend virtual or in-person conferences. Single day, local meetings are excluded.

Consulting

Consulting backlog represents future revenue to be derived from in-process consulting and benchmark analytics engagements.

Utilization rate represents a measure of productivity of our consultants. Utilization rates are calculated for billable headcount on a percentage basis by dividing total hours billed by total hours available to bill.



1Q 2023 GAAP Financial Statements



Condensed Consolidated Balance Sheets

Unaudited; in millions

Assets	M	larch 31, 2023	December 3 2022		
Current assets:					
Cash and cash equivalents	\$	893.5	\$	698.0	
Fees receivable		1,523.4		1,556.8	
Deferred commissions		343.7		363.1	
Prepaid expenses and other current assets		142.7		119.2	
Assets held-for-sale		<u> </u>		49.0	
Total current assets		2,903.3		2,786.1	
Property, equipment and leaseholds		256.9		264.6	
Operating leases - right of use assets		415.1		436.6	
Goodwill		2,929.9		2,930.2	
Intangible assets, net		564.1		584.7	
Other assets		309.6		297.5	
Total Assets	\$	7,378.9	\$	7,299.7	
Liabilities and Stockholders' Equity					
Current liabilities:					
Accounts payable and accrued liabilities	\$	838.8	\$	1,115.2	
Deferred revenues		2,607.1		2,443.8	
Current portion of long-term debt		8.4		7.8	
Liabilities held-for-sale				30.8	
Total current liabilities		3,454.3		3,597.6	
Long-term debt		2,452.4		2,453.6	
Operating leases - liabilities		575.9		597.3	
Other liabilities		423.4		423.4	
Total Liabilities		6,906.0		7,071.9	
Total Stockholders' Equity		472.9		227.8	
Total Liabilities and Stockholders' Equity	\$	7,378.9	\$	7,299.7	



Condensed Consolidated Statements of Operations

Unaudited; in millions, except per share amounts

Three Months Ended March 31,

	2023	 2022	
Revenues:			
Research	\$ 1,217.3	\$ 1,136.3	
Conferences	64.6	10.4	
Consulting	127.0	 116.0	
Total revenues	1,408.9	1,262.7	
Costs and expenses:			
Cost of services and product development	435.1	377.0	
Selling, general and administrative	657.1	618.0	
Depreciation	23.9	23.2	
Amortization of intangibles	22.7	25.1	
Acquisition and integration charges	1.4	2.2	
Gain from sale of divested operation	 (139.3)	 	
Total costs and expenses	1,000.9	1,045.5	
Operating income	408.0	217.2	
Interest expense, net	(27.4)	(31.4)	
Gain on event cancellation insurance claims	3.1		
Other (expense) income, net	 (2.4)	 29.2	
Income before income taxes	381.3	215.0	
Provision for income taxes	 85.5	 42.5	
Net income	\$ 295.8	\$ 172.5	
Net income per share:			
Basic	\$ 3.72	\$ 2.10	
Diluted	\$ 3.68	\$ 2.08	
Weighted average shares outstanding:	 		
Basic	 79.5	 82.0	
Diluted	80.3	83.0	



Three Months Ended March 31,

Condensed Consolidated Statement of Cash Flows

Unaudited; in millions

Net income \$ 295.8 \$ 172.5 Adjustments to reconcile net income to net cash provided by operating activities: 846.6 48.3 Depreciation and amortization 46.6 48.3 Stock-based compensation expense 45.0 32.1 Deferred taxes (7.9) (7.5) Gain from sale of divested operation (189.3) — Loss on impairment of lease related assets 8.7 23.9 Reduction in the carrying amount of operating lease right-of-use assets 17.6 18.0 Amortization and write-off of deferred financing fees 1.2 1.1 Loss (gain) on de-designated swaps 1.1 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: — — Fees receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (18.4) (11.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (28.2.2) 321.0	Operating activities:	2023		 2022
Depreciation and amortization 46.6 48.3 Stock-based compensation expense 45.0 32.1 Deferred taxes (7.9) (7.5) Gain from sale of divested operation (139.3) — Loss on impairment of lease related assets 8.7 23.9 Reduction in the carrying amount of operating lease right-of-use assets 17.6 18.0 Amortization and write-off of deferred financing fees 1.2 1.1 Loss (gain) on de-designated swaps 1.4 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: — 36.2 30.7 Peres receivable, net 36.2 30.7 18.9 19.6 18.9 Deferred commissions 19.6 18.9 18.9 11.1 10.3 10.4 10.9 11.9 10.6 18.9 11.9 10.6 18.9 11.9 10.6 18.9 11.9 10.6 18.9 11.9 10.6 18.9 11.9 10.6 18.9 11.9 10.6 10.6 10.6 11.9 10.6 10.6	Net income	\$	295.8	\$ 172.5
Stock-based compensation expense 45.0 32.1 Deferred taxes (7.9) (7.5) Gain from sale of divested operation (139.3) — Loss on impairment of lease related assets 8.7 23.9 Reduction in the carrying amount of operating lease right-of-use assets 17.6 18.0 Amortization and write-off of deferred financing fees 1.2 1.1 Loss (gain) on de-designated swaps 1.4 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: Teses receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6	Adjustments to reconcile net income to net cash provided by operating activities:			
Deferred taxes (7.9) (7.5) Gain from sale of divested operation (139.3) — Loss on impairment of lease related assets 8.7 23.9 Reduction in the carrying amount of operating lease right-of-use assets 17.6 18.0 Amortization and write-off of deferred financing fees 1.2 1.1 Loss (gain) on de-designated swaps 1.4 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: 36.2 30.7 Pees receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: 1 1 17.3 Additions to property, equipment and leasehold improvements (21.1) (17.3) Proceeds from sale of divested operation 158.7 —	Depreciation and amortization		46.6	48.3
Gain from sale of divested operation (139.3) — Loss on impairment of lease related assets 8.7 23.9 Reduction in the carrying amount of operating lease right-of-use assets 17.6 18.0 Amortization and write-off of deferred financing fees 1.2 1.1 Loss (gain) on de-designated swaps 1.4 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: 36.2 30.7 Peer receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: 17.4 6.9	Stock-based compensation expense		45.0	32.1
Loss on impairment of lease related assets 8.7 23.9 Reduction in the carrying amount of operating lease right-of-use assets 17.6 18.0 Amortization and write-off of deferred financing fees 1.2 1.1 Loss (gain) on de-designated swaps 1.4 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: Fees receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (18.7) (19.7) Other assets (19.7) (19.7) Other assets	Deferred taxes		(7.9)	(7.5)
Reduction in the carrying amount of operating lease right-of-use assets 17.6 18.0 Amortization and write-off of deferred financing fees 1.2 1.1 Loss (gain) on de-designated swaps 1.4 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: 36.2 30.7 Fees receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: 164.7 167.8 Investing activities: (21.1) (17.3) Additions to property, equipment and leasehold improvements (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: 137.6 (17.3) Proceeds from employee stock purchase plan 7.4	Gain from sale of divested operation	(139.3)	_
Amortization and write-off of deferred financing fees 1.2 1.1 Loss (gain) on de-designated swaps 1.4 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: 36.2 30.7 Fees receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: 164.7 167.8 Investing activities: (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: 137.6 (17.3) Proceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities </td <td>Loss on impairment of lease related assets</td> <td></td> <td>8.7</td> <td>23.9</td>	Loss on impairment of lease related assets		8.7	23.9
Loss (gain) on de-designated swaps 1.4 (29.9) Changes in assets and liabilities, net of acquisitions and divestitures: Fees receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: 1 1 (17.3) Additions to property, equipment and leasehold improvements (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: 137.6 (17.3) Proceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities (101.3) (455.0) Net increase (decrease) in cash and cash e	Reduction in the carrying amount of operating lease right-of-use assets		17.6	18.0
Changes in assets and liabilities, net of acquisitions and divestitures: 36.2 30.7 Fees receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: 164.7 167.8 Investing activities: (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: 137.6 (17.3) Proceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities (10.3) (445.5) Net increase (decrease) in cash and cash equivalents and restric	Amortization and write-off of deferred financing fees		1.2	1.1
Fees receivable, net 36.2 30.7 Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: (21.1) (17.3) Additions to property, equipment and leasehold improvements (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: 137.6 (17.3) Proceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities (106.9) (451.1) Cash used in financing activities (101.3) (445.5) Net increase (decrease) in cash and cash equivalents and	Loss (gain) on de-designated swaps		1.4	(29.9)
Deferred commissions 19.6 18.9 Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities:	Changes in assets and liabilities, net of acquisitions and divestitures:			
Prepaid expenses and other current assets (18.4) (13.6) Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities (101.3) (445.5) Net increase (decrease) in cash and cash equivalents and restricted cash 201.0 (295.0) Effects of exchange rates on cash and cash equivalents (5.5) (5.3) Cash and cash equivalents and restricted cash, beginning of period 698.6 760.6	Fees receivable, net		36.2	30.7
Other assets (14.8) (1.1) Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: 2 (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: 137.6 (17.3) Poceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities (101.3) (445.5) Net increase (decrease) in cash and cash equivalents and restricted cash 201.0 (295.0) Effects of exchange rates on cash and cash equivalents (5.5) (5.3) Cash and cash equivalents and restricted cash, beginning of period 698.6 760.6	Deferred commissions		19.6	18.9
Deferred revenues 155.2 195.4 Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: Additions to property, equipment and leasehold improvements (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: Proceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities (101.3) (445.5) Net increase (decrease) in cash and cash equivalents and restricted cash 201.0 (295.0) Effects of exchange rates on cash and cash equivalents (5.5) (5.3) Cash and cash equivalents and restricted cash, beginning of period 698.6 760.6	Prepaid expenses and other current assets		(18.4)	(13.6)
Accounts payable and accrued, and other liabilities (282.2) (321.0) Cash provided by operating activities 164.7 167.8 Investing activities: Additions to property, equipment and leasehold improvements (21.1) (17.3) Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: Proceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities Net increase (decrease) in cash and cash equivalents and restricted cash 201.0 (295.0) Effects of exchange rates on cash and cash equivalents Cash and cash equivalents and restricted cash, beginning of period 698.6 760.6	Other assets		(14.8)	(1.1)
Cash provided by operating activities164.7167.8Investing activities:(21.1)(17.3)Additions to property, equipment and leasehold improvements(21.1)(17.3)Proceeds from sale of divested operation158.7—Cash provided by (used in) investing activities137.6(17.3)Financing activities:******Proceeds from employee stock purchase plan7.46.9Payments on borrowings(1.8)(1.3)Purchases of treasury stock(106.9)(451.1)Cash used in financing activities(101.3)(445.5)Net increase (decrease) in cash and cash equivalents and restricted cash201.0(295.0)Effects of exchange rates on cash and cash equivalents(5.5)(5.3)Cash and cash equivalents and restricted cash, beginning of period698.6760.6	Deferred revenues		155.2	195.4
Investing activities:(21.1)(17.3)Additions to property, equipment and leasehold improvements(21.1)(17.3)Proceeds from sale of divested operation158.7—Cash provided by (used in) investing activities137.6(17.3)Financing activities:T.46.9Payments on borrowings(1.8)(1.3)Purchases of treasury stock(106.9)(451.1)Cash used in financing activities(101.3)(445.5)Net increase (decrease) in cash and cash equivalents and restricted cash201.0(295.0)Effects of exchange rates on cash and cash equivalents(5.5)(5.3)Cash and cash equivalents and restricted cash, beginning of period698.6760.6	Accounts payable and accrued, and other liabilities	(2	282.2)	(321.0)
Additions to property, equipment and leasehold improvements Proceeds from sale of divested operation Cash provided by (used in) investing activities Financing activities: Proceeds from employee stock purchase plan Payments on borrowings (1.8) Purchases of treasury stock Cash used in financing activities Net increase (decrease) in cash and cash equivalents and restricted cash Effects of exchange rates on cash and cash equivalents Cash and cash equivalents and restricted cash, beginning of period (21.1) (21.1) (21.1) (21.1) (21.1) (21.2) (17.3) (17.3) (17.3) (17.3) (17.3) (17.3) (17.3) (17.3) (18.5) (1.8) (1.8) (1.8) (1.8) (1.8) (1.8) (1.9) (2.9) (2.95.0) (2.95.0) (2.95.0) (2.95.0) (2.95.0)	Cash provided by operating activities		164.7	167.8
Proceeds from sale of divested operation 158.7 — Cash provided by (used in) investing activities 137.6 (17.3) Financing activities: Proceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities (101.3) (445.5) Net increase (decrease) in cash and cash equivalents and restricted cash 201.0 (295.0) Effects of exchange rates on cash and cash equivalents (5.5) (5.3) Cash and cash equivalents and restricted cash, beginning of period 698.6 760.6	Investing activities:			
Cash provided by (used in) investing activities137.6(17.3)Financing activities:Proceeds from employee stock purchase plan7.46.9Payments on borrowings(1.8)(1.3)Purchases of treasury stock(106.9)(451.1)Cash used in financing activities(101.3)(445.5)Net increase (decrease) in cash and cash equivalents and restricted cash201.0(295.0)Effects of exchange rates on cash and cash equivalents(5.5)(5.3)Cash and cash equivalents and restricted cash, beginning of period698.6760.6	Additions to property, equipment and leasehold improvements		(21.1)	(17.3)
Financing activities: Proceeds from employee stock purchase plan Payments on borrowings Purchases of treasury stock Cash used in financing activities Net increase (decrease) in cash and cash equivalents and restricted cash Effects of exchange rates on cash and cash equivalents Cash and cash equivalents and restricted cash, beginning of period Payments on proceeds (1.8) (1.8) (1.8) (1.8) (1.8) (1.8) (1.9) (451.1) (445.5) (5.5) (5.5) (5.3) Cash and cash equivalents and restricted cash, beginning of period	Proceeds from sale of divested operation		158.7	_
Proceeds from employee stock purchase plan 7.4 6.9 Payments on borrowings (1.8) (1.3) Purchases of treasury stock (106.9) (451.1) Cash used in financing activities (101.3) (445.5) Net increase (decrease) in cash and cash equivalents and restricted cash 201.0 (295.0) Effects of exchange rates on cash and cash equivalents (5.5) (5.3) Cash and cash equivalents and restricted cash, beginning of period 698.6 760.6	Cash provided by (used in) investing activities		137.6	(17.3)
Payments on borrowings(1.8)(1.3)Purchases of treasury stock(106.9)(451.1)Cash used in financing activities(101.3)(445.5)Net increase (decrease) in cash and cash equivalents and restricted cash201.0(295.0)Effects of exchange rates on cash and cash equivalents(5.5)(5.3)Cash and cash equivalents and restricted cash, beginning of period698.6760.6	Financing activities:			
Purchases of treasury stock(106.9)(451.1)Cash used in financing activities(101.3)(445.5)Net increase (decrease) in cash and cash equivalents and restricted cash201.0(295.0)Effects of exchange rates on cash and cash equivalents(5.5)(5.3)Cash and cash equivalents and restricted cash, beginning of period698.6760.6	Proceeds from employee stock purchase plan		7.4	6.9
Cash used in financing activities(101.3)(445.5)Net increase (decrease) in cash and cash equivalents and restricted cash201.0(295.0)Effects of exchange rates on cash and cash equivalents(5.5)(5.3)Cash and cash equivalents and restricted cash, beginning of period698.6760.6	Payments on borrowings		(1.8)	(1.3)
Net increase (decrease) in cash and cash equivalents and restricted cash201.0(295.0)Effects of exchange rates on cash and cash equivalents(5.5)(5.3)Cash and cash equivalents and restricted cash, beginning of period698.6760.6	Purchases of treasury stock	(106.9)	(451.1)
Effects of exchange rates on cash and cash equivalents(5.5)(5.3)Cash and cash equivalents and restricted cash, beginning of period698.6760.6	Cash used in financing activities	(101.3)	(445.5)
Cash and cash equivalents and restricted cash, beginning of period 698.6 760.6	Net increase (decrease) in cash and cash equivalents and restricted cash		201.0	(295.0)
	Effects of exchange rates on cash and cash equivalents		(5.5)	(5.3)
Cash and cash equivalents and restricted cash, end of period \$894.1 \$460.3			698.6	 760.6
	Cash and cash equivalents and restricted cash, end of period	\$	894.1	\$ 460.3



Non-GAAP Reconciliations



Non-GAAP Reconciliations

	lions

Reconciliation- Net Income to Adjusted EBITDA:	1Q22	2Q22	3Q22	4Q22	1Q23		(6
Net Income	172.5	204.9	173.5	256.8	295.8		
Interest expense, net	31.4	29.7	30.3	29.9	27.4		(k
Gain on event cancellation insurance claims (a)	_	_	_	_	(3.1)		(0
Other (income) expense, net	(29.2)	(8.5)	(8.9)	(1.7)	2.4		(
Tax provision	42.5	71.0	58.5	47.3	85.5		(4
Operating income	217.2	297.1	253.4	332.3	408.0		(0
Adjustments:							(
Stock-based compensation expense (b)	32.1	24.5	21.0	13.0	45.0		
Depreciation, accretion, and amortization (c)	48.6	47.9	47.5	48.9	46.9		
Loss on impairment of lease related assets (d)	23.9	11.6	2.0	16.4	8.7		(
Acquisition and integration charges and other nonrecurring items (e)	7.0	8.0	7.4	10.6	9.7		
Gain from sale of divested operation (f)	_	_	_	_	(139.3)		
Adjusted EBITDA	328.8	389.1	331.5	421.3	379.0		
\$ millions							
Reconciliation - Cash Provided by Operating Activities to Free Cash Flow:	2012	2013	2014	2015	2016	2017	201

- (a) Consists of the gain on event cancellation insurance claims for events cancelled in 2020.
- (b) Consists of charges for stock-based compensation.
- (c) Includes depreciation expense, amortization of intangibles, and accretion on asset retirement obligations.
- Includes impairment loss for lease related assets.
- (e) Consists of incremental and directlyrelated charges related to acquisitions and divestitures, facility-related exit costs, and other non-recurring items, if applicable.
- (f) Consists of the gain from the sale of our February 2023 divestiture.

Reconciliation - Cash Provided by Operating Activities to Free Cash Flow:	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Cash provided by operating activities	279.8	315.7	346.8	345.6	365.6	254.5	471.2	565.4	903.2	1,312.5
Less: cash paid for capital expenditures	(44.3)	(36.5)	(38.5)	(46.1)	(49.9)	(110.8)	(126.9)	(149.0)	(83.8)	(59.8)
Free Cash Flow	235.5	279.2	308.3	299.4	315.8	143.8	344.3	416.4	819.3	1,252.7

\$ millions

Reconciliation - Cash Provided by Operating Activities to Free Cash Flow:	1Q22	2Q22	3Q22	4Q22	1Q23
Cash provided by operating activities	167.8	415.6	314.8	203.1	164.7
Less: cash paid for capital expenditures	(17.3)	(21.1)	(32.1)	(37.6)	(21.1)
Free Cash Flow	150.5	394.5	282.7	165.5	143.6



Non-GAAP Reconciliations

In millions except per share amounts

Reconciliations - GAAP Net Income to Adjusted Net Income:	1Q22	2Q22	3Q22	4Q22	1Q23
GAAP net income	172.5	204.9	173.5	256.8	295.8
Acquisition and other adjustments:					
Amortization of acquired intangibles (a)	25.1	24.8	24.4	24.3	22.7
Acquisition and integration charges and other nonrecurring items (b)	8.2	9.1	8.7	11.8	10.9
Gain on event cancellation insurance claims (c)	_	_	_	_	(3.1)
Gain from sale of divested operation ^(d)	_	_	_	_	(139.3)
Loss on impairment of lease related assets (e)	23.9	11.6	2.0	16.4	8.7
(Gain) loss on de-designated interest rate swaps ^(f)	(29.9)	(10.7)	(11.2)	(0.6)	1.4
Tax impact of adjustments	(6.5)	(8.7)	(4.8)	(12.1)	34.3
Adjusted net income	193.3	231.0	192.7	296.7	231.5
Diluted shares	83.0	81.0	80.1	80.1	80.3
Adjusted EPS	2.33	2.85	2.41	3.70	2.88
Reconciliations - GAAP Net Income per diluted share to Adjusted EPS:	1Q22	2Q22	3Q22	4Q22	1Q23
GAAP net income per diluted share	2.08	2.53	2.17	3.21	3.68
Acquisition and other adjustments:					
Amortization of acquired intangibles (a)	0.30	0.31	0.30	0.30	0.28
Acquisition and integration charges and other nonrecurring items (b)	0.10	0.11	0.11	0.15	0.14
Gain on event cancellation insurance claims (c)	_	_	_	_	(0.04)
Gain from sale of divested operation ^(d)	_	_	_	_	(1.74)
Loss on impairment of lease related assets (e)	0.29	0.14	0.03	0.21	0.11
(Gain) loss on de-designated interest rate swaps ^(f)	(0.36)	(0.13)	(0.14)	(0.01)	0.02
Tax impact of adjustments	(80.0)	(0.11)	(0.06)	(0.15)	0.43
Adjusted EPS	2.33	2.85	2.41	3.70	2.88

- (a) Consists of non-cash amortization charges from acquired intangibles.
- (b) Consists of incremental and directlyrelated charges related to acquisitions and divestitures, facility-related exit costs, and other nonrecurring items, if applicable. Includes the amortization and write-off of deferred financing fees, which are recorded in Interest expense, net in the Consolidated Statements of Operations and in the Adj. EBITDA on the prior page.
- (c) Consists of the gain on event cancellation insurance claims for events cancelled in 2020.
- (d) Consists of the gain from the sale of our February 2023 divestiture.
- (e) Includes impairment loss for lease related assets.
- (f) Represents the fair value adjustment for interest rate swaps after de-designation.



Non-GAAP Reconciliations

\$ millions

•					
Reconciliation - Interest, net to Non-GAAP Interest, net	1Q22	2Q22	3Q22	4Q22	1Q23
Interest, net	31.4	29.7	30.3	29.9	27.4
Less amortization of deferred financing fees	(1.1)	(1.1)	(1.1)	(1.2)	(1.2)
Non-GAAP Interest, net	30.3	28.6	29.1	28.8	26.2
Effective GAAP Tax Rate to Non-GAAP Tax Rate:	1Q22	2Q22	3Q22	4Q22	1Q23
GAAP Rate	19.8 %	25.7 %	25.2 %	15.6 %	22.4 %
Acquisition and Other Adjustments	24.0 %	25.0 %	20.2 %	23.2 %	34.8 %
Non-GAAP Tax Rate	20.3 %	25.7 %	24.7 %	16.7 %	18.1 %



Non-GAAP Reconciliations - 2023 Guidance

Financial Outlook Reconciliation: GAAP Net Income to Adjusted EBITDA

(unaudited; \$ in millions) 2023 Gu		ance
	. •	7 04
GAAP net income	≥\$	761
Interest expense, net ^(a)	~	115
Gain on event cancellation insurance claims (b)	~	(3)
Other (income) expense, net	~	6
Tax provision	<u>~</u>	227
Operating Income	≥ 1	,106
Adjustments		
Stock-based compensation expense	~	132
Depreciation, accretion, and amortization	~	195
Acquisition and integration charges and other non-recurring items (c)	~	36
Gain from sale of divested operation (d)	<u>~</u>	(139)
Adjusted EBITDA	<u>≥\$</u>	1,330

Assumes approximately \$4M of amortization of deferred financing fees, which is reported in interest expense, net in the Company's Consolidated Statement of Operations.

Consists of the gain from the sale of our February 2023 divestiture.

Financial Outlook Reconciliation: GAAP Cash Provided by Operating Activities to Free Cash Flow:	2023 Guidance
GAAP cash provided by operating activities	≥\$1,030
Capital expenditures	~ (110)
Free Cash Flow	≥\$ 920

Financial Outlook Reconciliation: GAAP Diluted EPS to Adjusted EPS

(unaudited; \$ in millions)	2023 Guid	ance
GAAP Diluted EPS (a)	≥\$	9.48
Adjustments (after-tax):		
Amortization of acquired intangibles	~	0.84
Acquisition and integration charges and other non-recurring items (b)	~	0.39
Gain on event cancellation insurance claims (c)	~	(0.03)
Gain from sale of divested operation (d)	~	(1.18)
Adjusted EPS ^(a)	≥\$	9.50

⁽a) GAAP Diluted EPS and Adjusted EPS are calculated based on approximately 80M of diluted shares for 2023.



⁽b) Consists of the gain on event cancellation insurance claims for events cancelled in 2020.

^(c) Consists of incremental and directly-related charges related to acquisitions and divestitures, facility-related exit costs and other non-recurring items.

 ⁽b) Consists of incremental and directly-related charges related to acquisitions and divestitures, facility-related exit costs and other non-recurring items.
 (c) Consists of the gain on event cancellation insurance claims for events cancelled in 2020.

Consists of the gain from the sale of our February 2023 divestiture.